Power Law company profile

FibroGen

Biotech & Life Sciences · San Francisco, United States · Founded 1993 · IPO 2014 Thoroughbred

Discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs

Valuation

$88M

Market cap · Jan/2026

Revenue

$6.4M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

11 investors on FibroGen's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 11 investors entered at this stage

Astellas Pharma

Daiwa Securities Group

Merlin Biomed

BioFund Management

Goldman Sachs

The Rosewood Corporation

Brookside Capital

Apothecary Capital

Bain Capital

Sigma Capital Group

Adage Capital

Global footprint

Where FibroGen has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States66%

🇨🇳 China32.9%

🇵🇪 Peru0.6%

🇩🇰 Denmark0.6%

4 countries shown

Web traffic by country

3.6K monthly visits
across markets

🇺🇸 United States69.4%

🇯🇵 Japan27.8%

Top 2 markets shown

Market sentiment

What the market is saying about FibroGen

An AI-synthesized read of the highest-engagement posts about FibroGen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See FibroGen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles